Genzyme, US Bioservices join forces to launch educational services use of Carticel in to repair knee cartilage.Genzyme, Inc., Cambridge, MA, announced it has signed a partnership agreement with US Bioservices, xx, where, to provide Carticel C Care, a comprehensive clinical case support and health insurance authorized au·thor·ize tr.v. au·thor·ized, au·thor·iz·ing, au·thor·iz·es 1. To grant authority or power to. 2. To give permission for; sanction: services program for Carticel patients and their treating physicians. Carticel was the first biologic cell therapy licensed by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for orthopaedic surgeons to treat patients who have had an inadequate response to a prior treatment procedure. It is indicated for the repair of cartilage cartilage (kär`təlĭj), flexible semiopaque connective tissue without blood vessels or nerve cells. It forms part of the skeletal system in humans and in other vertebrates, and is also known as gristle. on the thigh bone (Anat.) the femur. See also: Thigh part of the knee caused by acute trauma. Genzyme says Carticel Care is a comprehensive support program that provides educational services and health care insurance support to patients who undergo the Carticel implant implant /im·plant/ (im-plant´) to insert or to graft (tissue, or inert or radioactive material) into intact tissues or a body cavity. procedure. Upon undergoing a cartilage biopsy, the patient will be enrolled in the program and a dedicated Carticel Care Coordinator, employed by US Bioservices, will be assigned to the case. The coordinator will be available to the patient throughout the treatment. Carticel was first licensed by the FDA in August 1998. Genzyme announced in June that Carticel therapy has been used in10,000 patients in the US. Contact: www.genzyme.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion